BigOmics Raises $1.85M to Revolutionize Omics Data Analytics

BigOmics raised $1.42 million on the first closing of its pre-series A round in October, 2021, after graduating from the US-based Alchemist Accelerator. The round, coordinated by TiVentures along with the participation of Century Oak Capital, Champion Hill Ventures and Acequia Capital, comes on top of the $430,000 funding raised earlier this year in a seed round from TiVentures and ADM Partners. Business angels Raul Vejar and Mark Jalabert, as well as Nathan Kaiser from the Swiss ICT Investor Club (SICTIC) network also joined the pre-series A round which remains open until January 2022 for additional funding. 

BigOmics' vision is to disrupt omics data analysis processes and accelerate scientific discovery. “Omics” is a part of biotechnology which analyzes the structure and functions of the whole makeup of a given biological function, at different levels, including the molecular gene level (“genomics”), the protein level (“proteomics”), and the metabolic level (“metabolomics”).

The company supports BioTech and Pharma companies, as well as academic labs, in the field of data-driven therapeutics and precision medicine to significantly reduce data analysis time and costs. BigOmics’ platforms enable omics data analysis stakeholders to communicate in an interactive manner instead of exchanging static analysis reports. They allow bioinformaticians to delegate part of their routine workload to biologists, while empowering the latter to take more control of their data analysis through a user-friendly interface. It is a win-win proposition for both biologists and bioinformaticians at enterprises and balances data quality and analysis agility.

Omics Playground is BigOmics’ flagship platform for visualizing and analyzing transcriptomics and proteomics data types. To date, the platform has been accessed by more than 16,000 users and the company has closed enterprise subscriptions with three BioTech & Pharma companies and two academic labs. 

BigOmics is a spin-off of the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana), Bellinzona, and the Dalle Molle Institute for Artificial Intelligence (IDSIA, joint institute of USI and SUPSI). The data analytics startup is currently incubated at the USI Startup Centre in Lugano

Murodzhon Akhmedov (CEO and Co-Founder) said: “We are excited to have been supported by dynamic VCs and angels in this new financing round in our mission to solve the omics data analysis bottleneck. This funding will enable us to expand our team and to actively commercialize our platform solutions.” 

Ivo Kwee (CTO and Co-Founder) added: “The closing of this first part of pre-series A funding will allow us to further support the development of our platforms and improve product-market-fit. We want to build the smoothest and most user-friendly platforms for omics data with a world-class team.”

Lorenzo Leoni (Managing Partner of TiVentures) commented: “With its unique software platforms, BigOmics can make a contribution to making drug development more efficient. Placed at the intersection of Biomedicine and Data Analytics, BigOmics represents the ideal company for TiVentures, focused on building high-value companies from advanced technologies.”